Cerus Corporation
Cerus Corporation (CERS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CERS · as of Jun 8, 2026
Key Statistics
Explore Cerus Corporation Data
cers stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 10 · Buy rate: 80.0%
The CERS analyst consensus is Buy, based on ratings from 10 Wall Street analysts over the past 3 months. The average 12-month price target is $4.00, representing +53.85% upside from the current price of $2.60.
Competitors & Peers
cers competitorsCERS
CVRX
MASS
NPCE
QTRX
RXSTStock Performance
Full HistoryAbout Cerus Corporation
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood …
what is cerus corporation · cers stock overview · cerus corporation company profile · who is cerus corporation ceo · cers NASDAQ · cerus corporation headquarters · cerus corporation business segments
About Stock Overview & Key Data
Cerus Corporation (CERS) is a Healthcare company in the Medical - Devices industry, listed on NASDAQ since Jan 31, 1997. As of the latest trading session, CERS stock price is $2.60, with a market capitalization of $521.0M. The stock has returned +78.23% over the past 12 months and +27.18% year-to-date.
According to 10 Wall Street analysts, the consensus rating for Cerus Corporation stock is Buy, with an average 12-month price target of $4.00. In fiscal year 2025, Cerus Corporation reported revenue of $206.1M and net income of -$15.6M. For detailed data — including Cerus Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Cerus Corporation (CERS) stock price is $2.60. The stock is traded on NASDAQ under the ticker symbol CERS. The 52-week range is $1.15 – $3.15.